Compare GCTS & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GCTS | ADAG |
|---|---|---|
| Founded | 1998 | 2011 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 206.9M | 222.2M |
| IPO Year | 2021 | 2020 |
| Metric | GCTS | ADAG |
|---|---|---|
| Price | $2.12 | $2.92 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $9.91 |
| AVG Volume (30 Days) | ★ 1.2M | 279.6K |
| Earning Date | 11-11-2026 | 08-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,866,000.00 | N/A |
| Revenue This Year | $772.99 | N/A |
| Revenue Next Year | $152.91 | $129.59 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.96 | $1.44 |
| 52 Week High | $3.93 | $4.85 |
| Indicator | GCTS | ADAG |
|---|---|---|
| Relative Strength Index (RSI) | 53.90 | 38.91 |
| Support Level | $1.70 | $2.80 |
| Resistance Level | $2.27 | $3.19 |
| Average True Range (ATR) | 0.12 | 0.27 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 57.86 | 28.74 |
GCT Semiconductor Holding Inc is a designer and supplier of 5G and 4G LTE semiconductor solutions. It enabled fast and reliable 4G LTE connectivity to numerous commercial devices such as CPEs, mobile hotspots, routers, M2M applications, and smartphones, etc. The system-on-chip solutions integrate radio frequency, baseband modem, and digital signal processing functions, therefore offering complete 4G and 5G platform solutions with small form factors, low power consumption, high performance, high reliability, and cost-effectiveness. Geographically, operates in South Korea and the United States, with maximum revenue from the USA.
Adagene Inc is a platform-driven, clinical-stage biotechnology company focused on the discovery and development of novel antibody-based cancer immunotherapies. The Company leverages computational biology to design and develop novel antibodies. Powered by its Dynamic Precision Library (DPL) platform, which fuels its NEObody, SAFEbody, and POWERbody technologies, it is developing a pipeline of immunotherapies. Its candidate, ADG126 (muzastotug), an anti-CTLA-4 SAFEbody, is in phase 1b/2 and phase 2 clinical development for metastatic microsatellite-stable colorectal cancer. Its clinical-stage products include ADG126 and ADG116, investigational fully human anti-CTLA-4 mAbs generated through SAFEbody and NEObody technologies.